TuHURA Starts Phase 3 Trial of IFx-2.0 With Keytruda
TuHURA has started a Phase 3 study combining IFx-2.0 with Keytruda for Merkel cell carcinoma.
Related stories
Enova Announces $600 Million Private Offering of Senior Notes Due 2031
M impact | EQUITY | Nov 04, 2026, 03:35 PM UTC
Kvika Q3 Pretax Profit Falls 11% to ISK 1.75 Billion
M impact | EQUITY | Nov 04, 2026, 03:35 PM UTC
US Gulf Coast Crude stock fell in the latest week to its lowest since December 2022 - EIA.
L impact | EQUITY | Nov 04, 2026, 03:35 PM UTC
Gibson Dunn in Talks to Hire About 120 Weil Lawyers
Gibson, Dunn & Crutcher is in talks to bring on around 120 lawyers from Weil, Gotshal & Manges in the United States and London, according to the report.
L impact | EQUITY | Nov 04, 2026, 03:35 PM UTC
Kvika Banki Reports Q3 2026 Financial Results
Kvika banki hf. reported return on tangible equity of 18.9% for the quarter.
M impact | EQUITY | Nov 04, 2026, 03:35 PM UTC
NYSE American single-stock trading halt, symbol not given — additional information requested (last $6.97)
NYSE American halted trading in a single listed security (additional information requested). Last price $6.97.
L impact | EQUITY | Nov 04, 2026, 03:35 PM UTC